The Association of the British Pharmaceutical Industry
Medicines are transforming our lives like never before.
We want the UK to be the best place in the world to research, develop and use the medicines and vaccines of the future.
- Valuing and accessing medicines
- RESEARCH, DEVELOPMENT AND MANUFACTURING
- WORKING IN PARTNERSHIP
- Industry Reputation
- International Policy, Trade & IP
- Health Data
Valuing and accessing medicines
Ensuring value, access and uptake of innovative medicines and vaccines, now and in the future
Medicines bring huge value to NHS patients. The development of new medicines is uncertain, costly, and involves significant rates of failure. The pharmaceutical industry spends $160 billion per year on research and development.The private sector produces nearly all the medicines and vaccines available to us. Companies need to make a profit – and a return – on global investment in order to maintain investment in the next generation of medicines.
RESEARCH, DEVELOPMENT AND MANUFACTURING
Improving the UK's attractiveness for industry, research, development and manufacturing
We're helping to build a thriving environment for medicine discovery so the UK can be the best place in the world to research and develop new medicines and vaccines.
WORKING IN PARTNERSHIP
Building better partnerships between industry and NHS and across the Life Sciences sector
We have a long-standing positive relationship with the NHS, and a record of facilitate the same across various parties across the Life Sciences sector. We believe in focusing collaboration on where it can add the most value in making innovation as widely available to patients as possible.
Industry Reputation
Building a stronger industry reputation in the UK
Everywhere, every day someone relies on the results of our work to ensure their health and wellbeing. We are proud of this and are committed to working with a wide range of people - patients, doctors, nurses, regulators and governments - in order to deliver medicines in an ethically responsible way. Patients are at the heart of everything that we do.
International Policy, Trade & IP
Providing international leadership and driving global policy
The ABPI is working to ensure that the UK has the best relationship with our international partners for patients, public health and the life sciences sector.
Health Data
Improving the UK's health data capability and industry's access to data
We aim to harness the UK’s health data to support the efficient design, feasibility, recruitment and conduct of the full range of clinical trials. We are helping the UK make the most of health-related data for future research and development into new medicines.
Life Sciences Superpower
A second report from PwC for the Association of the British Pharmaceutical Industry reveals why the UK needs to build its position as a world-leading hub for medicines development and discovery.
Read the Life Sciences Superpower report from PwC
Transforming lives, raising productivity
A new report from PwC for the Association of the British Pharmaceutical Industry reveals a picture of variable and slow access to the newest, innovative treatments.
Read the report from PwC on the value of medicinesLatest news
ABPI response to Clinical Research Implementation Plan publication
The governments of the four nations of the UK have published a second joint implementation plan for improving clinical research in the UK.
Latest Disclosure UK data: Highest ever rate of health professionals agreeing to be named
The latest information on ‘transfers of value’ made to healthcare organisations and health professionals in 2021 by pharmaceutical companies is published today on Disclosure UK.
Act now to bring £68bn economic boost to the UK through new research investment
The UK life science sector faces a “moment of truth” according to a new report produced by PwC for the ABPI.
ABPI welcomes Moderna investment
Moderna has signed an agreement with the UK Government to establish an mRNA Innovation and Technology Center in the UK.
Latest blogs and events
The Innovative Medicines Fund - Good news for patients but has an opportunity been missed to be more ambitious?
NHS England and Improvement (NHSE/I) has announced the launch of the Innovative Medicines Fund. The ABPI’s Director of Value and Access Policy, Paul Catchpole, provides further commentary on the announcement.
Working together, we are all determined to create more medicines for pregnant women
Steve Hoare, the ABPI's Head of Safety and Quality, talks about how industry is trying to address the lack of medicines approved for pregnant women.
Worth the wait – The Goldacre review
Our thoughts on Professor Ben Goldacre’s “Better, broader, safer” report into health data.
Innovative medicines can bring hope to people with rare diseases – let’s get them to patients
England’s Action Plan for Rare Diseases contains important commitments to ensure that people with rare diseases get faster diagnosis, better care and timelier access to the treatments they desperately need.
Key content hubs
We stand in solidarity with the people of Ukraine and condemn the invasion of their country. As an industry dedicated to saving lives, we stand for peace.
The COP26 summit will bring parties together to accelerate action towards the goals of the Paris Agreement and the UN Framework Convention on Climate Change.
As a critical part of the health care community in the UK, the pharmaceutical industry wants to play the biggest possible role in the response to COVID-19.
The ABPI Code of Practice sets out the requirements the industry must comply with and supports companies’ commitment to self-regulation and to operate in a professional, ethical and transparent manner.
Find out more about the potential of the UK’s life sciences sector if we deliver the government vision in full and at pace https://t.co/0biTNbQ6oS
— ABPI (@ABPI_UK) July 1, 2022
#ICYMI Yesterday, we launched a new report into the value that boosting the UK’s life sciences sector could deliver to the health and economy https://t.co/0biTNbQ6oS pic.twitter.com/dL5378tQ0a
— ABPI (@ABPI_UK) July 1, 2022
What is the potential of unlocking the power of the UK’s #LifeSciences sector?
— ABPI (@ABPI_UK) June 30, 2022
Our new report shows the economic and patient benefits to supporting our world-beating sector
Great to see the latest plan for all four nations of the UK to kickstart clinical research after the pandemic - read our response from @jnharris1189 🔬💉💊 https://t.co/e7v5NMWDOI
— ABPI (@ABPI_UK) June 30, 2022
The Pharmaceutical Industry in the UK
![Turnover [1]](/media/n5lbxuf1/figures-turnover-36-7bn.jpg)
![R and D Investment [2]](/media/4dufmenf/figures-r-d-investment-4-8bn.jpg)
Members
Online members portal (ABPI Meetings via Adam.ai)
ABPI members can log in for bespoke content and services.